Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 5/2008

Ausgabe 5/2008

Inhaltsverzeichnis ( 10 Artikel )

01.10.2008 | PHASE II STUDIES | Ausgabe 5/2008

Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

William C. Zamboni, Laura L. Jung, Sandra Strychor, Erin Joseph, Beth A. Zamboni, Sarah A. Fetterman, Brian J. Sidone, Thomas G. Burke, Dennis P. Curran, Julie L. Eiseman

01.10.2008 | PRECLINICAL STUDIES | Ausgabe 5/2008

Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil

Michael J. Kelner, Trevor C. McMorris, Rafael J. Rojas, Leita A. Estes, Pharnuk Suthipinijtham

01.10.2008 | PRECLINICAL STUDIES | Ausgabe 5/2008

Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [3 H]-rolipram binding in guinea pig tissues

Agnes L.-F. Chan, Hui-Lin Huang, Hui-Chi Chien, Chi-Ming Chen, Chun-Nan Lin, Wun-Chang Ko

01.10.2008 | PRECLINICAL STUDIES | Ausgabe 5/2008

Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by a new series of substituted-1,3,4-oxadiazole derivatives

Akhilesh Kumar, Saritha S. D’Souza, S. L. Gaonkar, K. M. L. Rai, Bharathi P. Salimath

01.10.2008 | PHASE I STUDIES | Ausgabe 5/2008

Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl-benzylidene)-thiazolidine-2,4-diones

S. Chandrappa, S. B. Benaka Prasad, K. Vinaya, C. S. Ananda Kumar, N. R. Thimmegowda, K. S. Rangappa

01.10.2008 | PHASE I STUDIES | Ausgabe 5/2008

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

Michael J. Overman, Gauri Varadhachary, Scott Kopetz, Melanie B. Thomas, Masakazu Fukushima, Keizo Kuwata, Akira Mita, Robert A. Wolff, Paulo M. Hoff, Henry Xiong, James L. Abbruzzese

01.10.2008 | PHASE I STUDIES | Ausgabe 5/2008

Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors

Patricia LoRusso, Elisabeth I. Heath, Jesse McGreivy, Yu-Nien Sun, Rebeca Melara, Lucy Yan, Lisa Malburg, Megan Ingram, Jeffrey Wiezorek, Li Chen, Mary Jo Pilat

01.10.2008 | PHASE II STUDIES | Ausgabe 5/2008

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Andrew H. Ko, Elizabeth Dito, Brian Schillinger, Alan P. Venook, Zhidong Xu, Emily K. Bergsland, Derrick Wong, Janet Scott, Jimmy Hwang, Margaret A. Tempero

01.10.2008 | PHASE II STUDIES | Ausgabe 5/2008

Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma

Dennis L. Carter, Lina Asmar, David Barrera, John Caracandas, J. Shaker Dakhil, Dean McCracken, Mark A. O’Rourke, Richard K. Rosenberg, Kristi A. Boehm, Des Ilegbodu, Robert L. Reid

01.10.2008 | PHASE II STUDIES | Ausgabe 5/2008

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

Johan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, Cong Chen, Justin L. Ricker, Sophia S. Randolph, Patrick Schöffski

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise